BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,130 filers reported holding BAXTER INTL INC in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,950,866 | -5.6% | 104,685 | +13.9% | 0.07% | -5.3% |
| Q2 2023 | $4,186,322 | +63.0% | 91,887 | +45.1% | 0.08% | +33.3% |
| Q1 2023 | $2,567,781 | -6.7% | 63,308 | +17.2% | 0.06% | -16.2% |
| Q4 2022 | $2,752,488 | -3.7% | 54,001 | +1.7% | 0.07% | -17.1% |
| Q3 2022 | $2,859,000 | -13.1% | 53,079 | +3.6% | 0.08% | -11.8% |
| Q2 2022 | $3,289,000 | -9.4% | 51,210 | +9.4% | 0.09% | 0.0% |
| Q1 2022 | $3,631,000 | +4.7% | 46,827 | +15.9% | 0.09% | +6.9% |
| Q4 2021 | $3,469,000 | +24.1% | 40,390 | +16.2% | 0.09% | +7.4% |
| Q3 2021 | $2,795,000 | +23.1% | 34,753 | +24.1% | 0.08% | +11.0% |
| Q2 2021 | $2,271,000 | +27.6% | 28,011 | +32.7% | 0.07% | +5.8% |
| Q1 2021 | $1,780,000 | +18.2% | 21,114 | +12.5% | 0.07% | +3.0% |
| Q4 2020 | $1,506,000 | +8.0% | 18,771 | +8.3% | 0.07% | -17.3% |
| Q3 2020 | $1,395,000 | +85.8% | 17,337 | +92.7% | 0.08% | +58.8% |
| Q2 2020 | $751,000 | -7.3% | 8,997 | -2.4% | 0.05% | -21.5% |
| Q1 2020 | $810,000 | -7.0% | 9,216 | -11.6% | 0.06% | -8.5% |
| Q4 2019 | $871,000 | +4.2% | 10,420 | -2.7% | 0.07% | +2.9% |
| Q3 2019 | $836,000 | -4.5% | 10,714 | +3.7% | 0.07% | -16.9% |
| Q2 2019 | $875,000 | -15.2% | 10,330 | -18.6% | 0.08% | +3.8% |
| Q1 2019 | $1,032,000 | +65.4% | 12,697 | +46.6% | 0.08% | -1.2% |
| Q4 2018 | $624,000 | – | 8,662 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tavio Capital LLC | 68,405 | $5,890,000 | 7.81% |
| Iron Triangle Partners LP | 330,000 | $28,413,000 | 7.16% |
| Veritas Asset Management LLP | 8,942,428 | $769,943,000 | 5.64% |
| TSFG, LLC | 93,405 | $8,042,000 | 5.31% |
| GENERATION INVESTMENT MANAGEMENT LLP | 10,606,094 | $913,185,000 | 5.27% |
| Third Point | 4,000,000 | $344,400,000 | 4.72% |
| Avidity Partners Management LP | 800,900 | $68,957,000 | 4.42% |
| Palmer Knight Co | 62,275 | $5,362,000 | 4.17% |
| Eos Focused Equity Management, L.P. | 36,786 | $3,167,000 | 3.70% |
| Dundas Partners LLP | 196,133 | $16,887,000 | 3.69% |